People with cystic fibrosis' experience of symptom burden while taking elexacaftor/tezacaftor/ivacaftor
Emily F Muther1, Sidney L Gibson2, Christine Ford3
1University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Background:
Despite improvements seen with elexacaftor/tezacaftor/ivacaftor (ETI), many people with CF (PWCF) still experience symptom burden. This study aimed to evaluate current perceived symptom burden and contrast it with PWCF's recollection of symptoms before starting ETI.
Methods:
Participants were 367 PWCF, ages 7-74 years (M age = 26.2), in the "Your ETI" (yETI) study. PWCF or caregivers of children (7-12 years) completed the Change in Perceptions of Health on ETI (CHETI) survey which assessed how often they were bothered by symptoms (respiratory, gastrointestinal/nutrition, sinus/pain, sleep/fatigue, and mental health/cognitive symptoms) before starting ETI and in the past month. A change score was calculated and categorized as less bothered, stable, or more bothered. Age differences were investigated.
Results:
Participants were on ETI for an average of 3.9 years. A notable percentage reported being less bothered by respiratory symptoms including cough (72%) and chest tightness (66%), and gastrointestinal symptoms including stomach pain/discomfort (48%), constipation, gas, bloating (46%), and difficulty gaining weight (51%). A smaller proportion indicated more bother related to weight gain (26%), increased appetite (23%), sleep difficulties (17%), and mental health/cognitive symptoms (14-22%). Participants reported the most current bother from constipation/gas/bloating (48%), anxiety (44%), sleep difficulties (44%), and anger/irritability (43%). Adults, notably those >36 years old, typically reported these symptoms more burdensome.
Conclusions:
While PWCF were bothered less by symptoms now compared to before starting ETI, some symptoms still caused a high degree of bother, particularly among 'older' adults with CF. Findings underscore the need for ongoing strategies to monitor and manage non-respiratory symptoms.
More Related Videos
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Asthma-III: Symptoms and Complications
Classification of Asthma
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
